Chart Industries (NYSE:GTLS – Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided EPS guidance of 9.000-9.000 for the period, compared to the consensus EPS estimate of 10.450. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.4 billion. Chart Industries also updated its FY 2025 guidance to 12.000-13.000 EPS.
Chart Industries Price Performance
NYSE GTLS traded up $11.43 on Monday, reaching $141.43. The company’s stock had a trading volume of 2,491,269 shares, compared to its average volume of 632,780. Chart Industries has a 52 week low of $101.60 and a 52 week high of $171.68. The firm has a market cap of $6.05 billion, a PE ratio of 40.96, a price-to-earnings-growth ratio of 0.56 and a beta of 1.71. The business has a 50-day moving average price of $121.62 and a 200 day moving average price of $136.90. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 1.28.
Chart Industries (NYSE:GTLS – Get Free Report) last announced its quarterly earnings results on Friday, November 1st. The industrial products company reported $2.18 earnings per share for the quarter, missing analysts’ consensus estimates of $2.56 by ($0.38). The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.10 billion. Chart Industries had a net margin of 2.80% and a return on equity of 12.27%. The business’s revenue was up 18.3% on a year-over-year basis. During the same quarter last year, the company earned $1.28 earnings per share. Sell-side analysts expect that Chart Industries will post 9.94 EPS for the current year.
Wall Street Analyst Weigh In
Get Our Latest Research Report on GTLS
Insider Transactions at Chart Industries
In related news, Director Linda S. Harty bought 5,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was bought at an average cost of $48.05 per share, for a total transaction of $240,250.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $240,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Chart Industries news, CEO Jillian C. Evanko acquired 440 shares of the stock in a transaction dated Thursday, September 5th. The shares were bought at an average cost of $114.31 per share, for a total transaction of $50,296.40. Following the completion of the acquisition, the chief executive officer now directly owns 125,448 shares of the company’s stock, valued at approximately $14,339,960.88. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Linda S. Harty bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was acquired at an average cost of $48.05 per share, with a total value of $240,250.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $240,250. The disclosure for this purchase can be found here. Insiders have purchased 7,152 shares of company stock worth $482,278 in the last three months. Insiders own 0.95% of the company’s stock.
Chart Industries Company Profile
Chart Industries, Inc engages in the designing, engineering, and manufacturing of process technologies and equipment for the gas and liquid molecules in the United States and internationally. The company operates in four segments: Cryo Tank Solutions, Heat Transfer Systems, Specialty Products, and Repair, Service & Leasing.
Read More
- Five stocks we like better than Chart Industries
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Intel: Is Now the Time to Be Brave?
- How Technical Indicators Can Help You Find Oversold Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Are Dividend Achievers? An Introduction
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Chart Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chart Industries and related companies with MarketBeat.com's FREE daily email newsletter.